CY1106246T1 - Ενωσεις δις(θειο-υδραζιδιο αμιδιου) για θepαπεια καρκινου διασταυρουμενης αντοχης - Google Patents

Ενωσεις δις(θειο-υδραζιδιο αμιδιου) για θepαπεια καρκινου διασταυρουμενης αντοχης

Info

Publication number
CY1106246T1
CY1106246T1 CY20061101668T CY061101668T CY1106246T1 CY 1106246 T1 CY1106246 T1 CY 1106246T1 CY 20061101668 T CY20061101668 T CY 20061101668T CY 061101668 T CY061101668 T CY 061101668T CY 1106246 T1 CY1106246 T1 CY 1106246T1
Authority
CY
Cyprus
Prior art keywords
substituted
group
aryl group
cross
aliphatic group
Prior art date
Application number
CY20061101668T
Other languages
English (en)
Inventor
Keizo Koya
Lijun Sun
Yaming Wu
Timoty Korbut
Dan Zhou
Zhenjian Du
Shoujun Chen
Noriaki Tatsuta
Guiqing Liang
Mitsunori Ono
Original Assignee
Synta Pharmaceuticals Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Pharmaceuticals Corporation filed Critical Synta Pharmaceuticals Corporation
Publication of CY1106246T1 publication Critical patent/CY1106246T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Μια απόδοση της παρούσας εφεύρεσης είναι μια μέθοδος θεραπείας ενός υποκειμένου το οποίο πάσχει από καρκίνο διασταυρούμενης αντοχής. Η μέθοδος περιλαμβάνει την χορήγηση στο υποκείμενο μιας αποτελεσματικής ποσότητας μιας ένωσης η οποία ένωση αναπαρίσταται στον Δομικό Χημικό Τύπο ( I ) : Το Υ είναι ένας ομοιοπολικός δεσμός ή μια υποκατεστημένη ή μη υποκατεστημένη ομάδα υδροκαρβυλ ευθείας αλυσίδας, ή, το Υ, μαζί με τις ομάδες › C = Ζ με τις οποίες βρίσκεται σε δεσμό, είναι μια υποκατεστημένη ή μη υποκατεστημένη αρωματική ομάδα. Τα R1 - R4 είναι ανεξάρτητα - Η, μια αλιφατική ομάδα, μια υποκατεστημένη αλιφατική ομάδα, μια ομάδα αρυλίου ή μια υποκατεστημένη ομάδα αρυλίου, ή ένα R1 και R3 μαζί με άτομα άνθρακα και νιτρογόνου με τα οποία βρίσκονται σε δεσμό, και / ή R2 και R4 μαζί με τα άτομα άνθρακα και νιτρογόνου με τα οποία βρίσκονται σε δεσμό, σχηματίζουν έναν μη - αρωματικό ετεροκυκλικό δακτύλιο επιλεκτικά τηγμένο σε έναν αρωματικό δακτύλιο. Κατά προτίμηση, το R1 και το R2 είναι ίδια μεταξύ τους και το R3 και το R4 είναι ίδια μεταξύ τους. Τα R5 - R6 είναι ανεξάρτητα - Η, μια αλιφατική ομάδα, μια υποκατεστημένη αλιφατική ομάδα, μια ομάδα αρυλίου ή μια υποκατεστημένη ομάδα αρυλίου. Το Ζ είναι = Ο ή = S.
CY20061101668T 2003-01-15 2006-11-16 Ενωσεις δις(θειο-υδραζιδιο αμιδιου) για θepαπεια καρκινου διασταυρουμενης αντοχης CY1106246T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44040603P 2003-01-15 2003-01-15
PCT/US2004/001089 WO2004064826A1 (en) 2003-01-15 2004-01-15 Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer

Publications (1)

Publication Number Publication Date
CY1106246T1 true CY1106246T1 (el) 2011-06-08

Family

ID=32771813

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101668T CY1106246T1 (el) 2003-01-15 2006-11-16 Ενωσεις δις(θειο-υδραζιδιο αμιδιου) για θepαπεια καρκινου διασταυρουμενης αντοχης

Country Status (14)

Country Link
US (1) US7763658B2 (el)
EP (1) EP1583524B1 (el)
JP (1) JP4852409B2 (el)
AT (1) ATE336991T1 (el)
AU (1) AU2004206865B2 (el)
CA (1) CA2512797C (el)
CY (1) CY1106246T1 (el)
DE (1) DE602004002087T2 (el)
DK (1) DK1583524T3 (el)
ES (1) ES2271839T3 (el)
HK (1) HK1084024A1 (el)
PT (1) PT1583524E (el)
TW (1) TWI330079B (el)
WO (1) WO2004064826A1 (el)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI297335B (en) * 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI332943B (en) 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI252847B (en) * 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
EP2574341B1 (en) 2004-03-29 2017-03-29 University Of South Florida Effective treatment of tumors and cancer with triciribine phosphate
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
WO2006009940A1 (en) 2004-06-23 2006-01-26 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) salts for treatment of cancers
US20060142393A1 (en) * 2004-09-16 2006-06-29 Sherman Matthew L Bis(thio-hydrazide amides) for treatment of hyperplasia
US20060167106A1 (en) * 2004-11-19 2006-07-27 Mei Zhang Compounds acting at the centrosome
WO2006055747A2 (en) * 2004-11-19 2006-05-26 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amides) for increasing hsp70 expression
JP2008536870A (ja) * 2005-04-15 2008-09-11 シンタ ファーマシューティカルズ コーポレーション 治療のためのナチュラルキラー細胞活性増強法
BRPI0610219A2 (pt) * 2005-04-15 2010-06-08 Synta Pharmaceuticals Corp métodos de tratamento de um ser humano com cáncer e composição de farmacêutica
JP2008540658A (ja) * 2005-05-16 2008-11-20 シンタ ファーマシューティカルズ コーポレーション ビス（チオ−ヒドラジドアミド）塩の合成
AU2006279891B2 (en) * 2005-08-16 2010-03-11 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) formulation
AU2007288334A1 (en) * 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
US20080176828A1 (en) * 2006-08-21 2008-07-24 Martin Williams Treating melanoma with BIS(THIOHYDRAZIDE AMIDES)
AU2007288337B2 (en) 2006-08-21 2012-02-16 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2008024305A2 (en) * 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis (thiohydrazide amides) for treating melanoma
WO2008024298A1 (en) * 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis(thiohydrazide amides) for inhibiting angiogenesis
WO2008024303A2 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
WO2008027445A2 (en) * 2006-08-31 2008-03-06 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
AU2007294969A1 (en) * 2006-09-11 2008-03-20 Synta Pharmaceuticals Corp. Bis (thiohydrazide amides) formulation
US9498528B2 (en) * 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
TW200829543A (en) 2006-09-15 2008-07-16 Synta Pharmaceuticals Corp Purification of bis(thiohydrazide amides)
US8618170B2 (en) * 2007-11-09 2013-12-31 Synta Pharmaceuticals Corp. Oral formulations of bis(thiohydrazide amides)
WO2009073148A2 (en) * 2007-11-28 2009-06-11 Synta Pharmaceuticals Corp. Polymorphs of n-malonyl-bis(n'-methyl-n'-thiobenzoylhydrazide)
US8581004B2 (en) 2008-02-21 2013-11-12 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US8633323B2 (en) * 2008-03-31 2014-01-21 Synta Pharmaceuticals Corp. Process for preparing bis(thiohydrazide amides)
AU2009308511B2 (en) 2008-10-22 2013-03-07 Synta Pharmaceutical Corp. Transition metal complexes of a bis[thiohydrazide amide] compound
US9174935B2 (en) 2008-10-22 2015-11-03 Synta Pharmaceuticals Corp. Transition metal complexes of bis[thiohydrazide amide] compounds
US8525776B2 (en) * 2008-10-27 2013-09-03 Lenovo (Singapore) Pte. Ltd Techniques for controlling operation of a device with a virtual touchscreen
US8680100B2 (en) 2008-12-01 2014-03-25 Synta Pharmaceuticals Corp. Sulfonylhydrazide compounds for treating proliferative disorders
US8822532B2 (en) 2009-12-04 2014-09-02 Synta Pharmaceuticals Corp. Bis[thiohydrazide amide] compounds for treating leukemia
US8815945B2 (en) 2010-04-20 2014-08-26 Masazumi Nagai Use of bis [thiohydrazide amide] compounds such as elesclomol for treating cancers
EP2776021A1 (en) * 2011-11-10 2014-09-17 Synta Pharmaceuticals Corp. Administration of a bis(thiohydrazide amide) compound for treating cancers
US20130149392A1 (en) 2011-12-12 2013-06-13 Synta Pharmaceuticals Corp. Method of treating non-small cell lung cancer with bis-(thiohydrazide)amide compounds
CN105764502A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群及其类似物及衍生物的治疗益处的组合方法
CN109640991A (zh) 2016-07-29 2019-04-16 詹森药业有限公司 治疗前列腺癌的方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2097737A5 (en) 1970-07-14 1972-03-03 Berlin Chemie Veb Virustatic 4-substd 1-acylthiosemicarbazides -from carboxylic acid - hydrazide and isothiocyanates or from carboxylic acid chloride and 4-
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
GB1272920A (en) 1971-03-15 1972-05-03 Berlin Chemie Veb New thiosemicarbazides
US4012360A (en) * 1973-12-03 1977-03-15 Ciba-Geigy Corporation Bis-salicyloyl-dicarboxylic acid dihydrazides as stabilizers for polyolefines
JPS5091056A (el) 1973-12-17 1975-07-21
US4822777A (en) * 1987-02-27 1989-04-18 Liposome Technology, Inc. Amphotericin B/cholesterol sulfate composition
JP2767241B2 (ja) * 1987-04-15 1998-06-18 ロ−ム アンド ハ−ス コンパニ− 殺虫性のｎ−（場合により置換された）−ｎ′−置換−ｎ，ｎ′−ジ置換ヒドラジン
US6013836A (en) * 1992-02-28 2000-01-11 Rohm And Haas Company Insecticidal N'-substituted-N,N'-disubstitutedhydrazines
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
CA2155947C (en) * 1993-02-22 2007-08-21 Mark W. Grinstaff Methods for in vivo delivery of biologics and compositions useful therefor
US5840746A (en) * 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US5523325A (en) * 1993-09-09 1996-06-04 Jacobson; Richard M. Amidrazones and their use as pesticides
BR9507914A (pt) * 1994-06-03 1997-09-23 Basf Ag Carbamoil-carbo hidrazida processo para preparar carbamoil-carbo-hidrazida composição adequada e processo para controlar fungos nocivos uso da carbamoil-carbo-hidrazida e amino-ácido-hidrazida
DE69604298T2 (de) * 1995-09-22 2000-05-18 Bioimage A/S, Soeborg Varianten des grünen fluoreszenzproteins, gfp
US5739686A (en) * 1996-04-30 1998-04-14 Naughton; Michael J. Electrically insulating cantilever magnetometer with mutually isolated and integrated thermometry, background elimination and null detection
US6235787B1 (en) * 1997-06-30 2001-05-22 Hoffmann-La Roche Inc. Hydrazine derivatives
GB9727524D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
TW479053B (en) * 1998-10-19 2002-03-11 Agro Kanesho Co Ltd Hydrazineoxoacetamide derivatives and pesticides
ES2161594B1 (es) * 1998-12-17 2003-04-01 Servier Lab Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
US6322303B1 (en) * 2000-05-12 2001-11-27 David M. John Dunnage bag and method of making same
EP1164126A1 (de) * 2000-06-16 2001-12-19 Basf Aktiengesellschaft Salicylsäurehydrazid-Derivate, Verfahren und Zwischenprodukte zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung zur Bekämpfung von Schadpilzen
US6365745B1 (en) * 2000-07-14 2002-04-02 Sumika Fine Chemicals Co., Ltd. Method for producing hydrazine derivative
JP2004532187A (ja) * 2001-01-25 2004-10-21 ギルフォード ファーマシュウティカルズ インコーポレイテッド 三置換カルボサイクリックサイクロフィリン結合化合物とその用途
EP1387684A1 (en) * 2001-05-01 2004-02-11 Abbott Laboratories Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents
US20040235813A1 (en) * 2001-05-03 2004-11-25 Erich Wanker Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation
US6602907B1 (en) * 2001-06-08 2003-08-05 University Of Central Florida Treatment of breast cancer
US6924312B2 (en) * 2001-07-10 2005-08-02 Synta Pharmaceuticals Corp. Taxol enhancer compounds
TWI252847B (en) * 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI332943B (en) 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI297335B (en) * 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI283670B (en) * 2001-11-28 2007-07-11 Sod Conseils Rech Applic 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as a medicament
TW200408407A (en) 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
AU2006228035B2 (en) 2003-01-15 2010-02-18 Synta Pharmaceuticals Corp. Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer
MXPA05008335A (es) 2003-02-11 2006-05-04 Vernalis Cambridge Ltd Compuestos de isoxazol como inhibidores de las proteinas de choque por calor.
KR100575251B1 (ko) 2003-03-03 2006-05-02 재단법인서울대학교산학협력재단 ｐ38／ＪＴＶ－1을 유효성분으로 하는 암 치료용 약학적조성물 및 암 치료용 약학적 조성물의 스크리닝 방법
EP1493445A1 (en) 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
KR100544347B1 (ko) * 2003-12-11 2006-01-23 한국생명공학연구원 디아릴이소옥사졸계 화합물을 유효성분으로 함유하는 암 예방 및 치료용 약학적 조성물
BRPI0509172A (pt) 2004-03-26 2007-08-28 Amphora Discovery Corp pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
WO2006009940A1 (en) * 2004-06-23 2006-01-26 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) salts for treatment of cancers
US20060142393A1 (en) * 2004-09-16 2006-06-29 Sherman Matthew L Bis(thio-hydrazide amides) for treatment of hyperplasia
WO2006055747A2 (en) 2004-11-19 2006-05-26 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amides) for increasing hsp70 expression
US20060167106A1 (en) * 2004-11-19 2006-07-27 Mei Zhang Compounds acting at the centrosome
BRPI0607688A2 (pt) 2005-02-17 2009-09-22 Synta Pharmaceuticals Corp método para inibir a polimerização de tubulina em uma célula; método para tratar ou prevenir um distúrbio proliferativo em um indivìduo; método para bloquear, ocluir ou de outro modo romper o fluxo sangüìneo na neovasculatura; composto; composição farmacêutica e uso do referido método e composto
BRPI0610219A2 (pt) 2005-04-15 2010-06-08 Synta Pharmaceuticals Corp métodos de tratamento de um ser humano com cáncer e composição de farmacêutica
WO2006113493A2 (en) 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Methods of determining cancer prognosis via natural killer cell activity
JP2008536870A (ja) 2005-04-15 2008-09-11 シンタ ファーマシューティカルズ コーポレーション 治療のためのナチュラルキラー細胞活性増強法
JP2008540658A (ja) 2005-05-16 2008-11-20 シンタ ファーマシューティカルズ コーポレーション ビス（チオ−ヒドラジドアミド）塩の合成
AU2006279891B2 (en) * 2005-08-16 2010-03-11 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) formulation
TW200804313A (en) 2006-05-25 2008-01-16 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 activity
WO2008024298A1 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis(thiohydrazide amides) for inhibiting angiogenesis
AU2007288334A1 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
US20080176828A1 (en) * 2006-08-21 2008-07-24 Martin Williams Treating melanoma with BIS(THIOHYDRAZIDE AMIDES)
WO2008024303A2 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2008024305A2 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis (thiohydrazide amides) for treating melanoma
AU2007288337B2 (en) 2006-08-21 2012-02-16 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2008027445A2 (en) 2006-08-31 2008-03-06 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
AU2007294969A1 (en) 2006-09-11 2008-03-20 Synta Pharmaceuticals Corp. Bis (thiohydrazide amides) formulation
WO2008033449A2 (en) 2006-09-14 2008-03-20 Synta Pharmaceuticals Corp. Compounds for the treatment of angiogenesis
TW200829543A (en) 2006-09-15 2008-07-16 Synta Pharmaceuticals Corp Purification of bis(thiohydrazide amides)
US20090093538A1 (en) 2007-01-03 2009-04-09 Synta Pharmaceuticals Corp Method for treating cancer
US8729111B2 (en) 2007-08-07 2014-05-20 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders

Also Published As

Publication number Publication date
PT1583524E (pt) 2006-12-29
EP1583524A1 (en) 2005-10-12
JP4852409B2 (ja) 2012-01-11
EP1583524B1 (en) 2006-08-23
AU2004206865A1 (en) 2004-08-05
US7763658B2 (en) 2010-07-27
ES2271839T3 (es) 2007-04-16
DK1583524T3 (da) 2006-12-27
US20040225016A1 (en) 2004-11-11
CA2512797A1 (en) 2004-08-05
CA2512797C (en) 2012-02-21
AU2004206865B2 (en) 2006-07-13
WO2004064826A1 (en) 2004-08-05
DE602004002087T2 (de) 2007-03-08
ATE336991T1 (de) 2006-09-15
TW200418449A (en) 2004-10-01
JP2006515626A (ja) 2006-06-01
DE602004002087D1 (de) 2006-10-05
TWI330079B (en) 2010-09-11
HK1084024A1 (en) 2006-07-21

Similar Documents

Publication Publication Date Title
CY1106246T1 (el) Ενωσεις δις(θειο-υδραζιδιο αμιδιου) για θepαπεια καρκινου διασταυρουμενης αντοχης
CY1105811T1 (el) Ενωσεις ενισχυτη ταξολης
MX2007012688A (es) Terapia de combinacion para el cancer con compuestos de bis(tiohidrazida) amida.
CY1111834T1 (el) Παραγωγα της 4-(2-αμινο-1-hydroxyethyl)phenol σαν αγωνιστικa του αδρενεργικου (adrenergic) ληπτη βητα -2
CY1110419T1 (el) Τρικυκλικες ενωσεις με βαση το 1,6-διυδρο-1,3,5,6-tetpaaza-as-ινδακενιο και φαρμακευτικες συνθεσεις που τις περιεχουν ως αναστολεις της ενζυμικης ενεργοτητας της ικκ
CY1115256T1 (el) Φαρμακευτικες ενωσεις
CY1118448T1 (el) Παραγωγο δικυκλοανιλινης
CY1111493T1 (el) Παραγωγα πυραζολιου ως τροποποιητες πρωτεϊνοκινασης
CY1112997T1 (el) ΝΕΑ ΠΑΡΑΓΩΓΑ ΙΜΙΔΑΖΟ[1,5-α]ΠΥΡΙΔΙΝΩΝ, Η ΔΙΑΔΙΚΑΣIΑ ΠΑΡΑΣΚΕΥΗΣ ΤΟΥΣ ΚΑΙ ΟΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΑ ΠΕΡΙΕΧΟΥΝ
CY1108127T1 (el) Μεθοδοι για την προστασια αλλογενους μοσχευματος παγκρεατικων νησιδιων με χρηση διαλυτων μοριων μεταλλακτων ctla4
CY1117392T1 (el) Ενδιαμεσες ενωσεις για την παρασκευη μακροκυκλικων αναστολεων του ιου της ηπατιτιδας c
CY1116119T1 (el) Παραγωγα ισοξαζολο-πυριδινης
ATE556085T1 (de) Phosphoramiditverbindung und verfahren zur herstellung von oligo-rna
EA200100600A3 (ru) Новые соединения дифенилмочевины, способ их получения и содержащие их фармацевтические композиции
CY1108183T1 (el) Θειαζολυλο-διυδρο-ινδαζολια
CO5721002A2 (es) Derivados de acido 3-(4-benciloxifenil) propanoico
CY1106858T1 (el) Νεα παραγωγα κυκλικου αμιδιου
GR1000684B (el) Μεθοδος παρασκευης παραγωγων ταξολης και τα εξ αυτης προκυπτοντα προιοντα.
CY1107532T1 (el) Παραγωγα ναφθυριδινης, παρασκευη και χρηση τους ως αναστολεις του ισοενζυμου 4 της φωσφοδιεστepασης (pde4)
CY1109327T1 (el) Μια μεθοδος για την παρασκευη εναντιομερικα καθαρης μιρταζαπινης
CY1105784T1 (el) Εκδοχα της πιπepαζινυλακυλπιπepιδινης η παρασκευη τους και η εφαρμογη τους στη θepαπευτικη
CY1113812T1 (el) Ετεροκυκλικη ενωση και φαρμακευτικη συνθεση αυτης
CY1110605T1 (el) Διαδικασια για την παρασκευη ενωσεων πυριμιδινης
FR2928151B1 (fr) Derives platine-carbene n-heterocyclique, leur preparation et leur application en therapeutique
CY1114869T1 (el) Παραγωγα 5-αμινο-2-(1-υδροξυ-αιθυλο)-τετραϋδροπυρανιου